Goldman Jonathan

SEC Form 4 insider trading activity

Goldman Jonathan has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Mar 31, 2026.

On the most recent filing, Goldman Jonathan is listed as Director at Avalo Therapeutics, Inc. Inside the rolling window, Goldman Jonathan reported no open-market purchases and 1 open-market sale totaling $163K in AVTX.

Companies traded

Other insiders at AVTX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$163K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
AVTX
Goldman Jonathan
Sale$163KNov 17SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Goldman Jonathan made?

Goldman Jonathan has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.

Which companies does Goldman Jonathan trade?

Goldman Jonathan has filed SEC Form 4 disclosures for 1 company, including AVTX.

When was Goldman Jonathan's most recent SEC Form 4 filing?

Goldman Jonathan's most recent SEC Form 4 filing on Tracefour is dated Mar 31, 2026.

What is Goldman Jonathan's total buy and sell value in the current window?

Inside the rolling retention window, Goldman Jonathan bought $0 and sold $163K based on SEC Form 4 filings.

What was Goldman Jonathan's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 11,367 AVTX shares on 2025-11-14, worth $163K, per SEC Form 4 filings.